Total Payments
$4,246
2024 Payments
$451.75
Companies
29
Transactions
211
Medicare Patients
2,316
Medicare Billing
$325,235
Payment Breakdown by Category
Food & Beverage$4,222 (99.4%)
Education$24.35 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,222 | 209 | 99.4% |
| Education | $24.35 | 2 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $740.07 | 49 | $0 (2023) |
| ABBVIE INC. | $739.51 | 46 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $706.85 | 20 | $0 (2024) |
| Kerecis Limited | $402.00 | 1 | $0 (2018) |
| Lilly USA, LLC | $375.82 | 28 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $175.39 | 5 | $0 (2023) |
| Amgen Inc. | $167.91 | 11 | $0 (2024) |
| Abbott Laboratories | $145.77 | 3 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $115.39 | 5 | $0 (2020) |
| SHIELD THERAPEUTICS INC | $99.94 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $451.75 | 17 | AstraZeneca Pharmaceuticals LP ($192.48) |
| 2023 | $454.55 | 15 | AstraZeneca Pharmaceuticals LP ($282.17) |
| 2022 | $1,145 | 55 | ABBVIE INC. ($220.81) |
| 2021 | $913.72 | 54 | AbbVie Inc. ($476.56) |
| 2020 | $226.72 | 17 | Novo Nordisk Inc ($132.08) |
| 2019 | $287.96 | 27 | Novo Nordisk Inc ($167.33) |
| 2018 | $553.01 | 14 | Kerecis Limited ($402.00) |
| 2017 | $212.94 | 12 | SANOFI-AVENTIS U.S. LLC ($72.06) |
All Payment Transactions
211 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Gastroenterology | ||||||
| 11/06/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: PSYCHIATRY | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/11/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 09/19/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: NEUROSCIENCE | ||||||
| 07/31/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.20 | General |
| Category: Inflammation | ||||||
| 07/16/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $99.94 | General |
| Category: Hematology | ||||||
| 07/16/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $11.88 | General |
| Category: Respiratory | ||||||
| 05/23/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $124.09 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/15/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: Inflammation | ||||||
| 04/03/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 04/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Education | In-kind items and services | $19.62 | General |
| Category: Cardio-renal | ||||||
| 03/13/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: Cardiology | ||||||
| 03/01/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: NEUROSCIENCE | ||||||
| 02/07/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/24/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: Respiratory | ||||||
| 11/29/2023 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Bone Health | ||||||
| 11/22/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Inflammation | ||||||
| 11/15/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: Respiratory | ||||||
| 10/10/2023 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/04/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: Diabetes | ||||||
| 09/27/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/20/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/23/2023 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 851 | 2,333 | $324,666 | $131,916 |
| 2022 | 12 | 516 | 1,039 | $192,936 | $70,492 |
| 2021 | 11 | 463 | 962 | $167,031 | $61,877 |
| 2020 | 9 | 486 | 1,005 | $183,776 | $60,950 |
Total Patients
2,316
Total Services
5,339
Medicare Billing
$325,235
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 154 | 417 | $68,388 | $25,884 | 37.8% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 111 | 604 | $54,065 | $25,113 | 46.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 124 | 210 | $50,820 | $18,287 | 36.0% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 31 | 204 | $31,416 | $11,407 | 36.3% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 34 | 89 | $18,067 | $7,841 | 43.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 57 | 57 | $15,048 | $7,836 | 52.1% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 34 | 202 | $22,018 | $7,825 | 35.5% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 56 | 135 | $10,125 | $5,032 | 49.7% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 16 | 80 | $12,320 | $4,998 | 40.6% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 30 | 32 | $11,744 | $4,738 | 40.3% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 46 | 46 | $3,520 | $3,293 | 93.6% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 18 | 66 | $9,768 | $2,780 | 28.5% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 15 | 30 | $6,090 | $2,516 | 41.3% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 20 | 54 | $4,698 | $1,773 | 37.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 45 | 45 | $1,515 | $1,361 | 89.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $2,662 | $476.60 | 17.9% |
| 90471 | Administration of vaccine | Office | 2023 | 19 | 21 | $987.00 | $288.08 | 29.2% |
| 90688 | Influenza vaccine, quadrivalent, 0.5 ml dosage | Office | 2023 | 13 | 13 | $650.00 | $265.98 | 40.9% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 17 | 17 | $765.00 | $203.52 | 26.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 156 | 452 | $74,164 | $27,611 | 37.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 99 | 157 | $37,994 | $12,253 | 32.2% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Facility | 2022 | 38 | 100 | $20,300 | $7,640 | 37.6% |
| 99306 | Initial nursing facility visit per day, typically 45 minutes | Facility | 2022 | 41 | 43 | $15,781 | $5,839 | 37.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 33 | 33 | $8,712 | $4,680 | 53.7% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Office | 2022 | 13 | 72 | $11,088 | $3,922 | 35.4% |
About Dr. Rajankumar Patel, M.D
Dr. Rajankumar Patel, M.D is a Geriatric Medicine healthcare provider based in Cherry Hill, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1396896023.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rajankumar Patel, M.D has received a total of $4,246 in payments from pharmaceutical and medical device companies, with $451.75 received in 2024. These payments were reported across 211 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($4,222).
As a Medicare-enrolled provider, Patel has provided services to 2,316 Medicare beneficiaries, totaling 5,339 services with total Medicare billing of $325,235. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Medicine
- Location Cherry Hill, NJ
- Active Since 01/16/2007
- Last Updated 04/02/2014
- Taxonomy Code 207QG0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1396896023
Products in Payments
- FARXIGA (Drug) $476.83
- UBRELVY (Drug) $435.07
- Ozempic (Drug) $254.98
- BREZTRI (Drug) $173.56
- TRULICITY (Drug) $171.82
- RYBELSUS (Drug) $166.49
- Rybelsus (Drug) $151.69
- QULIPTA (Drug) $147.34
- FREESTYLE LIBRE 2 (Device) $145.77
- VRAYLAR (Drug) $144.33
- JARDIANCE (Drug) $137.51
- EMGALITY (Drug) $109.18
- Tresiba (Drug) $101.69
- ACCRUFER (Drug) $99.94
- TOUJEO (Drug) $86.56
- Kerendia (Drug) $85.19
- Otezla (Drug) $62.03
- PAXLOVID (Drug) $60.85
- Repatha (Biological) $53.94
- XIFAXAN (Drug) $53.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.